Unfortunately these targetable mutations appear to be very rare in sarcomas, with clinical-grade panel sequencing of 259 synovial sarcomas failing to reveal any bearing BRAF V600E mutations [20]. This evidence concerns the gene BRAF and synovial sarcoma.